生长抑制素类似物市场 - 全球产业规模、份额、趋势、机会、预测：按类型、治疗、最终用途、地区和竞争格局划分，2021-2031年

全球生长抑制素类似物市场预计将从 2025 年的 62.8 亿美元成长到 2031 年的 94.9 亿美元，复合年增长率为 7.12%。

这些合成药物旨在模拟天然荷尔蒙生长抑制素的功能，主要作用是抑制生长激素、胰岛素和多种胃肠道激素的分泌。此市场的成长主要受神经内分泌肿瘤（NETs）和肢端肥大症发生率上升的驱动。这些疾病需要长期治疗以控制症状并阻止肿瘤进展。美国癌症协会估计，到2024年，美国每年将新增约8,000例胃肠道神经内分泌肿瘤病例，凸显了对持续治疗方案的需求。

然而，市场扩张面临一个重大障碍：学名药的日益普及。主要品牌药专利的到期使得低成本学名药药更容易进入市场，加剧了价格下行压力，降低了原厂药生产商的获利能力。这一趋势威胁着现有市场领导的盈利，因为它们正面临着来自更具成本效益的替代品的激烈竞争。

市场驱动因素

强大的临床研发管线和加速的监管核准正在从根本上重塑全球生长抑制素类似物市场，一种强效的口服替代疗法应运而生，成为标准注射剂型的有力替代方案。这种向非侵入性给药方式的转变有望减轻肢端肥大症和神经内分泌肿瘤患者长期注射的负担，并提高长期治疗依从性。例如，根据Crinetics Pharmaceuticals公司2024年3月公布的3期PATHFNDR-2试验结果，在研究性口服帕佐汀组中，56%的患者胰岛素样生长因子1 (IGF-1) 水平恢復正常，而安慰剂组仅为5%。这种口服製剂的高效性预示着疾病管理模式转移，并有望透过改善患者偏好和临床疗效，推动未来市场扩张。

同时，生长抑制素类似物在核医和治疗诊断学（治疗性诊断）领域的应用，正拓展这些药物的治疗效用，使其不再局限于症状控制，而是能够根除标靶肿瘤。胜肽受体放射性核种疗法（PRRT）是一种利用放射性标记的类似物将细胞毒性辐射特异性递送至生长抑制素受体阳性细胞的技术，目前正经历着快速的商业性化应用。根据诺华公司于2024年10月发布的2024年第三季财报，其放射性配体疗法Lutasera的季度销售额达到1.9亿美元，年增19%，反映出市场对标靶核医学介入的强劲需求。儘管创新正在加速发展，但成熟的治疗方法仍然是重要的收入来源。诺华指出，Sandostatin得定集团2023年的净销售额约为12.8亿美元，凸显了市场对基础生长抑制素类似物疗法的持续依赖。

市场挑战

学名药的日益普及对全球生长抑制素类似物市场的商业性扩张构成重大障碍。主要品牌药专利保护期的结束使得低成本替代品得以进入市场，从根本上扰乱了现有製药企业的收入结构。随着这些学名药渗透市场，价格下行压力将急剧上升，迫使原厂药企业削减成本以保持竞争力，否则将面临市场份额大幅下降的风险。这种从高价值品牌药转向以销售主导的学名药的转变，严重限制了企业维持该治疗领域研发持续投入所需的利润空间。

这种价值侵蚀的趋势得到了反映生长抑制素类似物当前处境的产业数据的佐证。根据美国可及药品协会（Association for Accessible Medicines）2024年的报告，学名药和生物相似药占美国所有处方笺的90%，但仅占药品总支出的约13%。处方量与经济回报之间如此巨大的差距清晰地揭示了这项挑战的机制。患者获得Octreotide和Lanreotide等治疗方法的机会可能会增加，但收入潜力与实际使用率的脱钩将抑制整体市场价值。

市场趋势

先进的、以患者为中心的自行注射装置的普及正在重塑市场格局，其优势在于优先考虑便利性和治疗依从性。与需要医疗专业人员注射的传统肌肉注射製剂不同，现代皮下缓释製剂整合了预填充式注射器，使患者能够独立管理治疗。这种朝向使用者友善给药系统的转变，为成熟品牌带来了显着的竞争优势，使其即使在充满挑战的市场环境中也能保持成长动能。根据益普生于2025年2月发布的《2024年全年业绩报告》，皮下缓释製剂生长激素（somatrin）的销售额同比增长5.6%，表明市场持续青睐集成于装置中的製剂，以最大限度地减少慢性病管理中的后勤负担。

同时，新一代多受体标靶类似物的研发正在拓展对标准疗法抗药性患者的治疗选择。第一代类似物主要与受体亚型2结合，而新一代药物如Pasireotide则对包括受体亚型1、3和5在内的多种受体具有高亲和性，在复杂病例中控制激素分泌过多方面疗效较佳。这种临床差异化显着促进了内分泌学领域内此类药物的商业性应用。根据RecoDati于2025年2月发布的“2024财年初步业绩报告”，内分泌部门净销售额达到3.217亿欧元，年增32.8%。这主要得益于多受体类似物Signifall的两位数成长，显示市场对更广泛的治疗选择有着强劲的需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：生长抑制素类似物的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（Octreotide、Lanreotide、Pasireotide）
  • 治疗类别（肢端肥大症、库欣氏症候群、神经内分泌肿瘤、类癌症候群、其他）
  • 依用途（医院/诊所、门诊手术中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美生长抑制素类似物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲生长抑制素类似物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区生长抑制素类似物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲生长抑制素类似物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲生长抑制素类似物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球生长抑制素类似物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Somatostatin Analogs Market is projected to expand from USD 6.28 Billion in 2025 to USD 9.49 Billion by 2031, registering a CAGR of 7.12%. These synthetic pharmacological agents are engineered to mimic the function of the natural hormone somatostatin, serving primarily to inhibit the secretion of growth hormone, insulin, and various gastrointestinal hormones. The market is largely propelled by the rising prevalence of neuroendocrine tumors (NETs) and acromegaly, conditions that require long-term management therapies to control symptoms and halt tumor progression. Highlighting the demand for sustained therapeutic options, the American Cancer Society estimated that approximately 8,000 neuroendocrine tumors originating in the gastrointestinal tract would be diagnosed annually in the United States in 2024.

However, market expansion faces a significant obstacle regarding the increasing availability of generic formulations. The expiration of patents for key branded drugs has facilitated the entry of lower-cost generic alternatives, which exerts downward pricing pressure and reduces the revenue potential for original manufacturers. This trend challenges the profitability of established market leaders as they face intensified competition from cost-effective substitutes.

Market Driver

A robust clinical pipeline and accelerated regulatory approvals are fundamentally reshaping the Global Somatostatin Analogs Market by introducing potent oral alternatives to standard injectables. This shift towards non-invasive delivery methods addresses the burden of chronic injections for patients with acromegaly and neuroendocrine tumors, promising to enhance long-term treatment adherence. For instance, according to Crinetics Pharmaceuticals' March 2024 'Phase 3 PATHFNDR-2 Study Results', 56% of participants receiving the investigational oral drug paltusotine achieved normalized insulin-like growth factor 1 (IGF-1) levels, compared to just 5% of those on placebo. This high efficacy rate for an oral agent signals a potential paradigm shift in disease management, likely driving future market expansion through improved patient preference and clinical outcomes.

Simultaneously, the integration of somatostatin analogs into nuclear medicine and theranostics is expanding the therapeutic utility of these agents beyond symptom control to targeted tumor eradication. Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled analogs to deliver cytotoxic radiation specifically to somatostatin receptor-positive cells, a modality experiencing rapid commercial uptake. According to Novartis' 'Q3 2024 Financial Results' released in October 2024, sales of the radioligand therapy Lutathera rose by 19% year-on-year to reach $190 million for the quarter, reflecting strong demand for targeted nuclear interventions. While innovation accelerates, established therapies remain vital revenue generators; Novartis noted that in 2023, the Sandostatin Group achieved total net sales of approximately $1.28 billion, underscoring the enduring market reliance on foundational somatostatin analog treatments.

Market Challenge

The increasing availability of generic formulations acts as a significant barrier to the commercial expansion of the global somatostatin analogs market. The loss of patent exclusivity for major branded drugs has enabled the entry of low-cost alternatives, which fundamentally disrupts the revenue structure of established pharmaceutical manufacturers. As these generic versions permeate the market, they create intense downward pricing pressure, forcing originators to lower costs to remain competitive or risk ceding substantial market share. This shift from high-value branded therapies to volume-driven generics severely limits the profit margins required to sustain continued investment in research and development for this therapeutic class.

This trend of value erosion is substantiated by broader industry data that reflects the environment somatostatin analogs now navigate. According to the Association for Accessible Medicines, in its 2024 report, generic and biosimilar medicines accounted for 90% of all prescriptions filled in the United States but represented only approximately 13% of total drug spending. This stark disparity between prescription volume and financial return illustrates the mechanics of the challenge; while patient access to therapies like octreotide and lanreotide may increase, the overall market value is constrained as revenue potential decouples from utilization rates.

Market Trends

The proliferation of advanced patient-centric self-injection devices is reshaping the market by prioritizing convenience and treatment adherence. Unlike traditional intramuscular formulations that often require administration by healthcare professionals, modern subcutaneous depots integrated with pre-filled syringes empower patients to manage their therapy independently. This shift towards user-friendly delivery systems has created a significant competitive advantage, allowing established brands to sustain momentum even amidst challenging market conditions. According to Ipsen's 'Full Year 2024 Results' published in February 2025, sales of the subcutaneous depot Somatuline grew by 5.6% year-on-year, illustrating the enduring market preference for device-integrated formulations that minimize the logistical burden of chronic disease management.

Concurrently, the development of next-generation multi-receptor targeted analogs is expanding therapeutic possibilities for patients refractory to standard treatments. While first-generation analogs primarily bind to receptor subtype 2, next-generation agents like pasireotide exhibit high affinity for multiple receptor subtypes, including 1, 3, and 5, offering superior efficacy in controlling hormone hypersecretion in complex cases. This clinical differentiation is driving substantial commercial uptake in the specialized endocrinology sector. According to Recordati's 'Preliminary Results for Full Year 2024' released in February 2025, the Endocrinology franchise achieved net revenue of €321.7 million, a 32.8% increase fueled by the double-digit growth of the multi-receptor analog Signifor, signaling strong demand for broader-spectrum therapeutic options.

Key Market Players

• Bayer AG
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Midatech Pharma plc
• Crinetics Pharmaceuticals Inc.
• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Mylan N.V

Report Scope

In this report, the Global Somatostatin Analogs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Somatostatin Analogs Market, By Type

• Octreotide
• Lanreotide
• Pasireotide

Somatostatin Analogs Market, By Treatment

• Acromegaly
• Cushing's Syndrome
• Neuroendocrine Tumors
• Carcinoid Syndrome
• Others

Somatostatin Analogs Market, By End Use

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Somatostatin Analogs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Somatostatin Analogs Market.

Available Customizations:

Global Somatostatin Analogs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Somatostatin Analogs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Octreotide, Lanreotide, Pasireotide)
  • 5.2.2. By Treatment (Acromegaly, Cushing's Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Others)
  • 5.2.3. By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Somatostatin Analogs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Somatostatin Analogs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Somatostatin Analogs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Somatostatin Analogs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End Use

7. Europe Somatostatin Analogs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Somatostatin Analogs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Somatostatin Analogs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Somatostatin Analogs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Somatostatin Analogs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Somatostatin Analogs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End Use

8. Asia Pacific Somatostatin Analogs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Somatostatin Analogs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Somatostatin Analogs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Somatostatin Analogs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Somatostatin Analogs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Somatostatin Analogs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Somatostatin Analogs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Somatostatin Analogs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Somatostatin Analogs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Somatostatin Analogs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End Use

10. South America Somatostatin Analogs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Somatostatin Analogs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Somatostatin Analogs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Somatostatin Analogs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Somatostatin Analogs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Midatech Pharma plc
• 15.6. Crinetics Pharmaceuticals Inc.
• 15.7. Peptron Inc.
• 15.8. Teva Pharmaceutical Industries Ltd.
• 15.9. Camurus AB
• 15.10. Mylan N.V

16. Strategic Recommendations

17. About Us & Disclaimer